The Task Force implies that risk-reducing interventions are not helpful for women with a BRCA1 mutation but no family history of cancer, but to our knowledge there is no evidence that the benefit of interventions for BRCA1 or BRCA2 carriers with bona fide mutations are modified by the family history. Here, BRCA1 is linked to cancer.